What Does the FDG-PET Scan Show in an Alzheimer’s Evaluation?

Learn which brain-activity pattern suggests Alzheimer's and how it guides your next care decisions.

An FDG-PET scan in an Alzheimer's evaluation shows how actively brain cells use energy. FDG-PET, a scan that uses a glucose-like tracer to map nerve-cell activity, most often shows low use in temporoparietal cortex, posterior cingulate and precuneus. That activity map helps doctors place memory and thinking symptoms in context. It reflects how brain cells are functioning, not only brain structure.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What pattern suggests Alzheimer's?

According to Diagnostic Radiation Physics Services brain PET guide, the classic finding is reduced metabolism on both sides of temporoparietal association cortex. The change is often asymmetric. Posterior cingulate and precuneus are commonly involved, with later spread to frontal cortex.

The tracer is fluorine-18 fluorodeoxyglucose, a glucose analog trapped after phosphorylation. It maps regional glucose use as an indirect measure of synaptic activity. The Journal of Nuclear Medicine diagnostic review notes relative sparing of primary sensorimotor and visual cortices, striatum, thalamus and cerebellum.

How does Alzheimer's differ from other dementias?

Different dementias weaken different brain networks. FDG-PET makes those topographies visible for comparison.

According to the Journal of Nuclear Medicine review of FDG imaging across degenerative dementias, the patterns separate as follows: A frontal-predominant pattern therefore points away from Alzheimer's. An occipital pattern with a spared cingulate island points toward Lewy-body disease.

  • Alzheimer's: temporoparietal and posterior cingulate low use
  • Frontotemporal dementia: frontal and anterior temporal low use
  • Dementia with Lewy bodies: occipital low use with cingulate island sparing

What does FDG add beyond MRI and amyloid tests?

The Society of Nuclear Medicine and Molecular Imaging patient materials explain that FDG-PET can show abnormal function before major volume loss appears on CT or MRI. Affected neurons consume less energy before they shrink. That timing can clarify early or uncertain symptoms.

Under the NIA-Alzheimer's Association AT(N) framework, described in the 2021 framework review in PMC, FDG hypometabolism is an "N" neurodegeneration marker. It does not directly show amyloid "A" plaques. It also does not directly show tau "T" tangles.

What are the limits and practical next steps?

The American Society of Neuroradiology and SNMMI emphasize that the Alzheimer-like biparietal pattern is predictive but not definitive alone. Doctors interpret FDG-PET with history, neurologic exam, structural imaging and other biomarkers.

One scan does not replace clinical judgment. According to the Centers for Medicare and Medicaid Services in its Medicare dementia PET coverage rule, Medicare covers FDG-PET to separate frontotemporal dementia from Alzheimer's when specified clinical requirements are met, or in a CMS-approved study of FDG-PET utility. Practical steps include:.

  • Bring symptom timeline, exam notes and MRI or CT results
  • Ask whether FDG-PET would change diagnosis or care
  • Confirm referral, coverage and preparation rules before scheduling

You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.